NICE rejects Erbitux in head and neck cancer

pharmafile | June 24, 2009 | News story | Research and Development, Sales and Marketing |ย ย Erbitux, Merck Serono, NICEย 

Related Content

Digital mental health technologies โ€“ a valuable tool in supporting people with depression and anxiety

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

Combination treatments: Takedaโ€™s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content